跳至主要内容
临床试验/NCT02237742
NCT02237742已完成1 期

A Phase 1, Non-Randomized, Open-Label, Single-Dose, Single Period Study With Non-Pharmacologically Active Dose Of Pf-06427878 To Characterize Pharmacokinetics Following Intravenous Administration In Healthy, Adult, Male Subjects

Pfizer1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2014年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
6
试验地点
1
主要终点
Area Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast)

研究概览

简要总结

To determine how the body reacts to a low dose of PF-06427878 when given in a vein over 30 minutes to healthy, adult, males.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male subjects between 18-55 years of age
  • BMI of 17.5-30.5 kg/m2

排除标准

  • History of drug or alcohol abuse within 2 years of screening
  • Subjects without suitable veins for multiple venipuncture/cannulation

研究组 & 干预措施

PF-06427878

Experimental

干预措施: PF-06427878 (Drug)

结局指标

主要结局

Area Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast)

时间窗: Day 1 Min 0,5,15,30,35,45,60,75,90, Hr 2,2.5,3.5,4.5,5.5,6.5,8.5,10.5,12.5,24.5

Area under the Plasma Concentration-Time Curve From Time Zero extrapolated to Infinite Time (AUCinf)

时间窗: Day 1 Min 0,5,15,30,35,45,60,75,90, Hr 2,2.5,3.5,4.5,5.5,6.5,8.5,10.5,12.5,24.5

Maximum Observed Plasma Concentration (Cmax)

时间窗: Day 1 Min 0,5,15,30,35,45,60,75,90, Hr 2,2.5,3.5,4.5,5.5,6.5,8.5,10.5,12.5,24.5

Plasma Terminal Elimination Half Life (t1/2)

时间窗: Day 1 Min 0,5,15,30,35,45,60,75,90, Hr 2,2.5,3.5,4.5,5.5,6.5,8.5,10.5,12.5,24.5

Plasma Systemic Clearance (CL)

时间窗: Day 1 Min 0,5,15,30,35,45,60,75,90, Hr 2,2.5,3.5,4.5,5.5,6.5,8.5,10.5,12.5,24.5

Plasma Volume of Distribution at Steady State (Vss)

时间窗: Day 1 Min 0,5,15,30,35,45,60,75,90, Hr 2,2.5,3.5,4.5,5.5,6.5,8.5,10.5,12.5,24.5

次要结局

  • Amount of unchanged drug excreted in urine from time 0 to 12.5 hours (Ae12.5)(Day 1 Hr 0 to 12.5)
  • Percent of dose excreted in urine as unchanged drug from time zero to 12.5 hours (Ae12.5%)(Day 1 Hr 0 to 12.5)
  • Renal clearance (CLr)(Day 1 Hr 0 to 12.5)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验